董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rebecca Chambers | 女 | Director | 48 | 未披露 | 未持股 | 2026-03-27 |
| Yuling Luo | 男 | Chief Executive Officer and Chairman | 63 | 327.60万美元 | 620.78 | 2026-03-27 |
| Shiping Chen | 男 | Chief Operating Officer and Director | 64 | 157.85万美元 | 205.87 | 2026-03-27 |
| Nicholas Naclerio | 男 | Director | 65 | 未披露 | 612.83 | 2026-03-27 |
| Ian W. Ratcliffe | 男 | Director | 65 | 未披露 | 未持股 | 2026-03-27 |
| Frank R. Witney | 男 | Director | 73 | 未披露 | 6.07 | 2026-03-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yuling Luo | 男 | Chief Executive Officer and Chairman | 63 | 327.60万美元 | 620.78 | 2026-03-27 |
| Timothy White | 男 | President | 59 | 未披露 | 未持股 | 2026-03-27 |
| Justin McAnear | 男 | Chief Financial Officer | 51 | 193.75万美元 | 未持股 | 2026-03-27 |
| Shiping Chen | 男 | Chief Operating Officer and Director | 64 | 157.85万美元 | 205.87 | 2026-03-27 |
董事简历
中英对照 | 中文 | 英文- Rebecca Chambers
-
Rebecca Chambers自2019年6月起担任我们的首席财务官。钱伯斯女士从基因工具公司Illumina加入该公司，她在该公司担任过多个职位:2017年7月至2019年5月，担任Vice President、财务规划和分析，担任Vice President，2015年4月至2017年6月担任投资者关系和财政部高级总监，2012年10月至2015年4月担任投资者关系高级总监。此前，Chambers从2011年1月到2012年10月担任Myriad Genetics（一家分子诊断公司）投资者关系和企业传播主管，从2009年5月到2010年12月担任Life Technologies（一家生物技术公司）投资者关系高级经理。她此前也曾担任Bank of America（金融服务公司）、Millennium Pharmaceuticals（生物制药公司）的职务。Chambers女士拥有John Carroll大学学士学位和康奈尔大学S.C.Johnson管理研究生院工商管理硕士学位。
Rebecca Chambers has served as our Chief Financial Officer since June 2019. Ms. Chambers joined the Company from Illumina, a genetic tools company, where she served in a number of roles: as the Vice President, Financial Planning and Analysis from July 2017 to May 2019 as Vice President, Investor Relations and Treasury from April 2015 to June 2017 and as Senior Director, Investor Relations from October 2012 to April 2015. Previously, Ms. Chambers served as Head of Investor Relations and Corporate Communications at Myriad Genetics, a molecular diagnostic company, from January 2011 to October 2012 and Senior Manager, Investor Relations at Life Technologies, a biotechnology company, from May 2009 to December 2010. She also previously held positions with Bank of America, a financial services company, and Millennium Pharmaceuticals, a biopharmaceutical company. Ms. Chambers holds a B.S. from John Carroll University and an M.B.A. from The S.C. Johnson Graduate School of Management, Cornell University. - Rebecca Chambers自2019年6月起担任我们的首席财务官。钱伯斯女士从基因工具公司Illumina加入该公司，她在该公司担任过多个职位:2017年7月至2019年5月，担任Vice President、财务规划和分析，担任Vice President，2015年4月至2017年6月担任投资者关系和财政部高级总监，2012年10月至2015年4月担任投资者关系高级总监。此前，Chambers从2011年1月到2012年10月担任Myriad Genetics（一家分子诊断公司）投资者关系和企业传播主管，从2009年5月到2010年12月担任Life Technologies（一家生物技术公司）投资者关系高级经理。她此前也曾担任Bank of America（金融服务公司）、Millennium Pharmaceuticals（生物制药公司）的职务。Chambers女士拥有John Carroll大学学士学位和康奈尔大学S.C.Johnson管理研究生院工商管理硕士学位。
- Rebecca Chambers has served as our Chief Financial Officer since June 2019. Ms. Chambers joined the Company from Illumina, a genetic tools company, where she served in a number of roles: as the Vice President, Financial Planning and Analysis from July 2017 to May 2019 as Vice President, Investor Relations and Treasury from April 2015 to June 2017 and as Senior Director, Investor Relations from October 2012 to April 2015. Previously, Ms. Chambers served as Head of Investor Relations and Corporate Communications at Myriad Genetics, a molecular diagnostic company, from January 2011 to October 2012 and Senior Manager, Investor Relations at Life Technologies, a biotechnology company, from May 2009 to December 2010. She also previously held positions with Bank of America, a financial services company, and Millennium Pharmaceuticals, a biopharmaceutical company. Ms. Chambers holds a B.S. from John Carroll University and an M.B.A. from The S.C. Johnson Graduate School of Management, Cornell University.
- Yuling Luo
-
罗玉玲，是Alamar Biosciences，Inc.的联合创始人，自2018年5月起担任Alamar Biosciences，Inc.首席执行官和Alamar Biosciences，Inc.董事会主席。罗博士还与他人共同创立了Attovia Therapeutics，Inc.，他自2022年12月起担任该公司的董事。罗博士还与他人共同创立了英伟达生物医学公司，并于2019年1月起担任董事，直到2022年12月该公司被安捷伦科技公司收购。2016年8月至2018年2月，罗博士担任生物技术研究公司Bio-Techne Corporation Advanced Cell Diagnostics总裁。罗博士还与他人共同创立了Advanced Cell Diagnostics，Inc.，从2006年起担任总裁兼首席执行官，直到2016年该公司被Bio-Techne Corporation收购。在其职业生涯的早期，罗博士在生命科学公司Panomics，Inc.创立并担任过各种职务，在肿瘤学公司Exelixis, Inc.担任高级科学家。罗博士获中国科学技术大学化学学士学位，凯斯西储大学生物化学博士。
Yuling Luo,is Alamar Biosciences, Inc. co-founder and has served as Alamar Biosciences, Inc. Chief Executive Officer and as Chairman of Alamar Biosciences, Inc. board of directors since May 2018. Dr. Luo also co-founded Attovia Therapeutics, Inc., where he has served a director since December 2022. Dr. Luo also co-founded Avida Biomed Inc., where he served as a director from January 2019 until it was acquired by Agilent Technologies, Inc. in December 2022. From August 2016 to February 2018, Dr. Luo served as President, Advanced Cell Diagnostics of Bio-Techne Corporation a biotechnology research company. Dr. Luo also co-founded Advanced Cell Diagnostics, Inc. where he served as President and Chief Executive Officer from 2006 until it was acquired by Bio-Techne Corporation in 2016. Earlier in his career, Dr. Luo founded and served in various roles at Panomics, Inc., a life sciences company, and as a Senior Scientist at Exelixis, Inc., an oncology company. Dr. Luo received his B.S. in Chemistry from the University of Science and Technology of China and holds a Ph.D. in Biochemistry from Case Western Reserve University. - 罗玉玲，是Alamar Biosciences，Inc.的联合创始人，自2018年5月起担任Alamar Biosciences，Inc.首席执行官和Alamar Biosciences，Inc.董事会主席。罗博士还与他人共同创立了Attovia Therapeutics，Inc.，他自2022年12月起担任该公司的董事。罗博士还与他人共同创立了英伟达生物医学公司，并于2019年1月起担任董事，直到2022年12月该公司被安捷伦科技公司收购。2016年8月至2018年2月，罗博士担任生物技术研究公司Bio-Techne Corporation Advanced Cell Diagnostics总裁。罗博士还与他人共同创立了Advanced Cell Diagnostics，Inc.，从2006年起担任总裁兼首席执行官，直到2016年该公司被Bio-Techne Corporation收购。在其职业生涯的早期，罗博士在生命科学公司Panomics，Inc.创立并担任过各种职务，在肿瘤学公司Exelixis, Inc.担任高级科学家。罗博士获中国科学技术大学化学学士学位，凯斯西储大学生物化学博士。
- Yuling Luo,is Alamar Biosciences, Inc. co-founder and has served as Alamar Biosciences, Inc. Chief Executive Officer and as Chairman of Alamar Biosciences, Inc. board of directors since May 2018. Dr. Luo also co-founded Attovia Therapeutics, Inc., where he has served a director since December 2022. Dr. Luo also co-founded Avida Biomed Inc., where he served as a director from January 2019 until it was acquired by Agilent Technologies, Inc. in December 2022. From August 2016 to February 2018, Dr. Luo served as President, Advanced Cell Diagnostics of Bio-Techne Corporation a biotechnology research company. Dr. Luo also co-founded Advanced Cell Diagnostics, Inc. where he served as President and Chief Executive Officer from 2006 until it was acquired by Bio-Techne Corporation in 2016. Earlier in his career, Dr. Luo founded and served in various roles at Panomics, Inc., a life sciences company, and as a Senior Scientist at Exelixis, Inc., an oncology company. Dr. Luo received his B.S. in Chemistry from the University of Science and Technology of China and holds a Ph.D. in Biochemistry from Case Western Reserve University.
- Shiping Chen
-
陈世平，是Alamar Biosciences，Inc.的联合创始人，自2018年8月起担任Alamar Biosciences，Inc.首席运营官，自2020年5月起担任Alamar Biosciences，Inc.董事会成员。2016年8月至2018年8月，陈博士在生物技术研究公司Bio-Techne Corporation担任先进细胞诊断部门的首席运营官。陈博士还与人共同创立了Advanced Cell Diagnostics，Inc.，这是一家诊断公司，他在2008年至2016年期间担任首席运营官。在其职业生涯早期，他曾在物流自动化公司Power Automation Systems担任工程总监，并与他人共同创立并担任生命科学公司Panomics，Inc.的首席技术官。此外，陈博士此前还曾担任马里兰大学机械工程学助理教授和伦敦南岸大学电气工程学高级讲师。陈博士获得中国科学技术大学精密仪器仪表工程学士学位，并获得伦敦大学电气与电子工程博士学位。
Shiping Chen,is Alamar Biosciences, Inc. co-founder and has served as Alamar Biosciences, Inc. Chief Operating Officer since August 2018 and as a member of Alamar Biosciences, Inc. board of directors since May 2020. From August 2016 to August 2018, Dr. Chen served as Chief Operating Officer of the Advanced Cell Diagnostics division at Bio-Techne Corporation, a biotechnology research company. Dr. Chen also co-founded Advanced Cell Diagnostics, Inc., a diagnostics company, where he served as Chief Operating Officer from 2008 to 2016. Earlier in his career, he served as Director of Engineering at Power Automation Systems, a logistics automation company, and co-founded and served as Chief Technology Officer of Panomics, Inc., a life sciences company. Additionally, Dr. Chen previously served as Assistant Professor of Mechanical Engineering at the University of Maryland and as a Senior Lecturer of Electrical Engineering at London South Bank University from. Dr. Chen received his B.S. in Precision Instrumentation Engineering from the University of Science and Technology of China and obtained a Ph.D. in Electrical and Electronic Engineering from the University of London. - 陈世平，是Alamar Biosciences，Inc.的联合创始人，自2018年8月起担任Alamar Biosciences，Inc.首席运营官，自2020年5月起担任Alamar Biosciences，Inc.董事会成员。2016年8月至2018年8月，陈博士在生物技术研究公司Bio-Techne Corporation担任先进细胞诊断部门的首席运营官。陈博士还与人共同创立了Advanced Cell Diagnostics，Inc.，这是一家诊断公司，他在2008年至2016年期间担任首席运营官。在其职业生涯早期，他曾在物流自动化公司Power Automation Systems担任工程总监，并与他人共同创立并担任生命科学公司Panomics，Inc.的首席技术官。此外，陈博士此前还曾担任马里兰大学机械工程学助理教授和伦敦南岸大学电气工程学高级讲师。陈博士获得中国科学技术大学精密仪器仪表工程学士学位，并获得伦敦大学电气与电子工程博士学位。
- Shiping Chen,is Alamar Biosciences, Inc. co-founder and has served as Alamar Biosciences, Inc. Chief Operating Officer since August 2018 and as a member of Alamar Biosciences, Inc. board of directors since May 2020. From August 2016 to August 2018, Dr. Chen served as Chief Operating Officer of the Advanced Cell Diagnostics division at Bio-Techne Corporation, a biotechnology research company. Dr. Chen also co-founded Advanced Cell Diagnostics, Inc., a diagnostics company, where he served as Chief Operating Officer from 2008 to 2016. Earlier in his career, he served as Director of Engineering at Power Automation Systems, a logistics automation company, and co-founded and served as Chief Technology Officer of Panomics, Inc., a life sciences company. Additionally, Dr. Chen previously served as Assistant Professor of Mechanical Engineering at the University of Maryland and as a Senior Lecturer of Electrical Engineering at London South Bank University from. Dr. Chen received his B.S. in Precision Instrumentation Engineering from the University of Science and Technology of China and obtained a Ph.D. in Electrical and Electronic Engineering from the University of London.
- Nicholas Naclerio
-
Nicholas Naclerio，自2020年5月起担任Alamar Biosciences，Inc.董事会成员。Naclerio博士是依诺米那 Ventures的创始合伙人，自2016年4月起担任该职位。纳克莱里奥博士目前在多家私营公司的董事会任职。在其职业生涯的早期，Naclerio博士曾于2010年7月至2015年4月担任基因组学公司Illumina, Inc.的企业与风险发展高级副总裁。Naclerio博士还与他人共同创立了诊断公司Quanterix Corporation，并于2007年至2010年担任董事会主席兼首席执行官。Naclerio博士在杜克大学获得电气工程/计算机科学学士学位，在马里兰大学学院公园获得电气工程博士学位。
Nicholas Naclerio,has served as a member of Alamar Biosciences, Inc. board of directors since May 2020. Dr. Naclerio is the Founding Partner of Illumina Ventures, a position he has held since April 2016. Dr. Naclerio currently serves on the boards of directors of a number of privately held companies. Earlier in his career, Dr. Naclerio served as Senior Vice President, Corporate & Venture Development of Illumina, Inc., a genomics company, from July 2010 to April 2015. Dr. Naclerio also co-founded Quanterix Corporation, a diagnostics company, and served as the Chairman of the Board and Chief Executive Officer from 2007 to 2010. Dr. Naclerio received his B.S. in Electrical Engineering/Computer Science from Duke University and a Ph.D. in Electrical Engineering from the University of Maryland College Park. - Nicholas Naclerio，自2020年5月起担任Alamar Biosciences，Inc.董事会成员。Naclerio博士是依诺米那 Ventures的创始合伙人，自2016年4月起担任该职位。纳克莱里奥博士目前在多家私营公司的董事会任职。在其职业生涯的早期，Naclerio博士曾于2010年7月至2015年4月担任基因组学公司Illumina, Inc.的企业与风险发展高级副总裁。Naclerio博士还与他人共同创立了诊断公司Quanterix Corporation，并于2007年至2010年担任董事会主席兼首席执行官。Naclerio博士在杜克大学获得电气工程/计算机科学学士学位，在马里兰大学学院公园获得电气工程博士学位。
- Nicholas Naclerio,has served as a member of Alamar Biosciences, Inc. board of directors since May 2020. Dr. Naclerio is the Founding Partner of Illumina Ventures, a position he has held since April 2016. Dr. Naclerio currently serves on the boards of directors of a number of privately held companies. Earlier in his career, Dr. Naclerio served as Senior Vice President, Corporate & Venture Development of Illumina, Inc., a genomics company, from July 2010 to April 2015. Dr. Naclerio also co-founded Quanterix Corporation, a diagnostics company, and served as the Chairman of the Board and Chief Executive Officer from 2007 to 2010. Dr. Naclerio received his B.S. in Electrical Engineering/Computer Science from Duke University and a Ph.D. in Electrical Engineering from the University of Maryland College Park.
- Ian W. Ratcliffe
-
Ian W. Ratcliffe，自2024年2月起担任Alamar Biosciences，Inc.董事会成员。Ratcliffe先生是Life Sciences Pulse战略的执行管理合伙人，也是Sands Capital的执行董事总经理。拉特克利夫先生于2016年加入金沙资本。他是一名连续创业者，拥有20年作为天使、风险投资、私募股权投资人开始和投资生命科学技术业务的经验。Ratcliffe先生曾担任多个角色，担任多家私营生命科学产品和服务企业的创始人、首席执行官、首席财务官、首席运营官、董事长、董事和顾问。他专注于细胞信号传导、药物筛选、基因组学和测序、细胞培养和修饰细分领域，在业务发展的从发起到盈利到贸易销售的各个阶段。在加入Sands Capital之前，Ratcliffe先生是Enzymatics Inc.的董事长兼首席执行官、干细胞和iPS细胞生命科学工具公司Stemgent，Inc.的创始人兼首席执行官，以及细胞信号研究产品和服务的领先供应商Upstate Inc.的总裁。拉特克利夫先生还是金沙资本投资的Firefly Bioworks和Genometry的创始投资者。拉特克利夫先生拥有萨里大学化学工程学位，并拥有弗吉尼亚大学达顿学院的工商管理硕士学位。
Ian W. Ratcliffe,has served as a member of Alamar Biosciences, Inc. board of directors since February 2024. Mr. Ratcliffe is an Executive Managing Partner of the Life Sciences Pulse strategy and an Executive Managing Director of Sands Capital. Mr. Ratcliffe joined Sands Capital in 2016. He is a serial entrepreneur and has 20 years of experience starting and investing in life sciences technology businesses as an angel, venture, and private equity investor. Mr. Ratcliffe has served in many roles as a founder, CEO, CFO, COO, chairman, director, and advisor to a number of privately held life science product and service businesses. He has focused on the cell signaling, drug screening, genomics, and sequencing, and cell culture and modification segments, at all stages of business development from initiation through profitability to trade sale. Prior to joining Sands Capital, Mr. Ratcliffe was the Chairman and CEO of Enzymatics Inc., founder and CEO of Stemgent, Inc., a stem and iPS cell life sciences tools company, and President of Upstate Inc., a leading provider of cell signaling research products and services. Mr. Ratcliffe was also a founding investor in Firefly Bioworks and Genometry, both Sands Capital investments. Mr. Ratcliffe has a degree in Chemical Engineering from the University of Surrey and has an M.B.A. from the Darden School at the University of Virginia. - Ian W. Ratcliffe，自2024年2月起担任Alamar Biosciences，Inc.董事会成员。Ratcliffe先生是Life Sciences Pulse战略的执行管理合伙人，也是Sands Capital的执行董事总经理。拉特克利夫先生于2016年加入金沙资本。他是一名连续创业者，拥有20年作为天使、风险投资、私募股权投资人开始和投资生命科学技术业务的经验。Ratcliffe先生曾担任多个角色，担任多家私营生命科学产品和服务企业的创始人、首席执行官、首席财务官、首席运营官、董事长、董事和顾问。他专注于细胞信号传导、药物筛选、基因组学和测序、细胞培养和修饰细分领域，在业务发展的从发起到盈利到贸易销售的各个阶段。在加入Sands Capital之前，Ratcliffe先生是Enzymatics Inc.的董事长兼首席执行官、干细胞和iPS细胞生命科学工具公司Stemgent，Inc.的创始人兼首席执行官，以及细胞信号研究产品和服务的领先供应商Upstate Inc.的总裁。拉特克利夫先生还是金沙资本投资的Firefly Bioworks和Genometry的创始投资者。拉特克利夫先生拥有萨里大学化学工程学位，并拥有弗吉尼亚大学达顿学院的工商管理硕士学位。
- Ian W. Ratcliffe,has served as a member of Alamar Biosciences, Inc. board of directors since February 2024. Mr. Ratcliffe is an Executive Managing Partner of the Life Sciences Pulse strategy and an Executive Managing Director of Sands Capital. Mr. Ratcliffe joined Sands Capital in 2016. He is a serial entrepreneur and has 20 years of experience starting and investing in life sciences technology businesses as an angel, venture, and private equity investor. Mr. Ratcliffe has served in many roles as a founder, CEO, CFO, COO, chairman, director, and advisor to a number of privately held life science product and service businesses. He has focused on the cell signaling, drug screening, genomics, and sequencing, and cell culture and modification segments, at all stages of business development from initiation through profitability to trade sale. Prior to joining Sands Capital, Mr. Ratcliffe was the Chairman and CEO of Enzymatics Inc., founder and CEO of Stemgent, Inc., a stem and iPS cell life sciences tools company, and President of Upstate Inc., a leading provider of cell signaling research products and services. Mr. Ratcliffe was also a founding investor in Firefly Bioworks and Genometry, both Sands Capital investments. Mr. Ratcliffe has a degree in Chemical Engineering from the University of Surrey and has an M.B.A. from the Darden School at the University of Virginia.
- Frank R. Witney
-
Frank R. Witney，自2026年1月起担任Alamar Biosciences，Inc.董事会成员，自2021年4月起担任顾问。Witney博士自2016年9月起担任私募股权公司Ampersand Capital Partners的运营合伙人。在此之前，Witney博士于2011年7月至2016年3月期间担任生命科学、细胞生物学和诊断产品提供商Affymetrix, Inc.（“Affymetrix”）的总裁兼首席执行官。此前，Witney博士曾于2009年4月至2011年5月担任分析仪器及相关配件和化学品供应商戴安的总裁兼首席执行官。在其职业生涯早期，Witney博士曾于2008年12月至2009年4月担任Affymetrix的执行副总裁兼首席商务官，并于2002年7月至2008年12月担任Panomics Inc.的总裁兼首席执行官。Witney博士目前在血液安全上市公司Cerus Corporation、生命科学诊断上市公司Revvity，Inc.、生命科学工具上市公司Standard BioTools，Inc.以及多家私营公司的董事会任职。Witney博士还曾在2021年至2024年期间担任Telesis Bio，Inc.的董事，该公司是一家公开上市的合成生物学公司。Witney博士获得了伊利诺伊大学的微生物学学士学位以及印第安纳大学的微生物学硕士学位和分子和细胞生物学博士学位。
Frank R. Witney,has served as a member of Alamar Biosciences, Inc. board of directors since January 2026 and a consultant since April 2021. Dr. Witney has served as an operating partner at Ampersand Capital Partners, a private equity firm, since September 2016. Prior to that, Dr. Witney served as President and Chief Executive Officer of Affymetrix, Inc. ("Affymetrix"), a provider of life science, cell biology and diagnostic products from July 2011 to March 2016. Previously, Dr. Witney served as President and Chief Executive Officer of Dionex Corporation, a provider of analytical instrumentation and related accessories and chemicals from April 2009 to May 2011. Earlier in his career, Dr. Witney served as Affymetrix's Executive Vice President and Chief Commercial Officer from December 2008 to April 2009 and President and Chief Executive Officer of Panomics Inc. from July 2002 to December 2008. Dr. Witney currently serves on the board of directors of Cerus Corporation, a publicly traded blood safety company, Revvity, Inc., a publicly traded life sciences diagnostics company, and Standard BioTools, Inc., a publicly traded life science tools company, as well as several privately held companies. Dr. Witney also served as a director of Telesis Bio, Inc., a publicly traded synthetic biology company from 2021 to 2024. Dr. Witney earned a B.S. in Microbiology from the University of Illinois as well as a M.S. in Microbiology and a Ph.D. in Molecular and Cellular Biology from Indiana University. - Frank R. Witney，自2026年1月起担任Alamar Biosciences，Inc.董事会成员，自2021年4月起担任顾问。Witney博士自2016年9月起担任私募股权公司Ampersand Capital Partners的运营合伙人。在此之前，Witney博士于2011年7月至2016年3月期间担任生命科学、细胞生物学和诊断产品提供商Affymetrix, Inc.（“Affymetrix”）的总裁兼首席执行官。此前，Witney博士曾于2009年4月至2011年5月担任分析仪器及相关配件和化学品供应商戴安的总裁兼首席执行官。在其职业生涯早期，Witney博士曾于2008年12月至2009年4月担任Affymetrix的执行副总裁兼首席商务官，并于2002年7月至2008年12月担任Panomics Inc.的总裁兼首席执行官。Witney博士目前在血液安全上市公司Cerus Corporation、生命科学诊断上市公司Revvity，Inc.、生命科学工具上市公司Standard BioTools，Inc.以及多家私营公司的董事会任职。Witney博士还曾在2021年至2024年期间担任Telesis Bio，Inc.的董事，该公司是一家公开上市的合成生物学公司。Witney博士获得了伊利诺伊大学的微生物学学士学位以及印第安纳大学的微生物学硕士学位和分子和细胞生物学博士学位。
- Frank R. Witney,has served as a member of Alamar Biosciences, Inc. board of directors since January 2026 and a consultant since April 2021. Dr. Witney has served as an operating partner at Ampersand Capital Partners, a private equity firm, since September 2016. Prior to that, Dr. Witney served as President and Chief Executive Officer of Affymetrix, Inc. ("Affymetrix"), a provider of life science, cell biology and diagnostic products from July 2011 to March 2016. Previously, Dr. Witney served as President and Chief Executive Officer of Dionex Corporation, a provider of analytical instrumentation and related accessories and chemicals from April 2009 to May 2011. Earlier in his career, Dr. Witney served as Affymetrix's Executive Vice President and Chief Commercial Officer from December 2008 to April 2009 and President and Chief Executive Officer of Panomics Inc. from July 2002 to December 2008. Dr. Witney currently serves on the board of directors of Cerus Corporation, a publicly traded blood safety company, Revvity, Inc., a publicly traded life sciences diagnostics company, and Standard BioTools, Inc., a publicly traded life science tools company, as well as several privately held companies. Dr. Witney also served as a director of Telesis Bio, Inc., a publicly traded synthetic biology company from 2021 to 2024. Dr. Witney earned a B.S. in Microbiology from the University of Illinois as well as a M.S. in Microbiology and a Ph.D. in Molecular and Cellular Biology from Indiana University.
高管简历
中英对照 | 中文 | 英文- Yuling Luo
罗玉玲，是Alamar Biosciences，Inc.的联合创始人，自2018年5月起担任Alamar Biosciences，Inc.首席执行官和Alamar Biosciences，Inc.董事会主席。罗博士还与他人共同创立了Attovia Therapeutics，Inc.，他自2022年12月起担任该公司的董事。罗博士还与他人共同创立了英伟达生物医学公司，并于2019年1月起担任董事，直到2022年12月该公司被安捷伦科技公司收购。2016年8月至2018年2月，罗博士担任生物技术研究公司Bio-Techne Corporation Advanced Cell Diagnostics总裁。罗博士还与他人共同创立了Advanced Cell Diagnostics，Inc.，从2006年起担任总裁兼首席执行官，直到2016年该公司被Bio-Techne Corporation收购。在其职业生涯的早期，罗博士在生命科学公司Panomics，Inc.创立并担任过各种职务，在肿瘤学公司Exelixis, Inc.担任高级科学家。罗博士获中国科学技术大学化学学士学位，凯斯西储大学生物化学博士。
Yuling Luo,is Alamar Biosciences, Inc. co-founder and has served as Alamar Biosciences, Inc. Chief Executive Officer and as Chairman of Alamar Biosciences, Inc. board of directors since May 2018. Dr. Luo also co-founded Attovia Therapeutics, Inc., where he has served a director since December 2022. Dr. Luo also co-founded Avida Biomed Inc., where he served as a director from January 2019 until it was acquired by Agilent Technologies, Inc. in December 2022. From August 2016 to February 2018, Dr. Luo served as President, Advanced Cell Diagnostics of Bio-Techne Corporation a biotechnology research company. Dr. Luo also co-founded Advanced Cell Diagnostics, Inc. where he served as President and Chief Executive Officer from 2006 until it was acquired by Bio-Techne Corporation in 2016. Earlier in his career, Dr. Luo founded and served in various roles at Panomics, Inc., a life sciences company, and as a Senior Scientist at Exelixis, Inc., an oncology company. Dr. Luo received his B.S. in Chemistry from the University of Science and Technology of China and holds a Ph.D. in Biochemistry from Case Western Reserve University.- 罗玉玲，是Alamar Biosciences，Inc.的联合创始人，自2018年5月起担任Alamar Biosciences，Inc.首席执行官和Alamar Biosciences，Inc.董事会主席。罗博士还与他人共同创立了Attovia Therapeutics，Inc.，他自2022年12月起担任该公司的董事。罗博士还与他人共同创立了英伟达生物医学公司，并于2019年1月起担任董事，直到2022年12月该公司被安捷伦科技公司收购。2016年8月至2018年2月，罗博士担任生物技术研究公司Bio-Techne Corporation Advanced Cell Diagnostics总裁。罗博士还与他人共同创立了Advanced Cell Diagnostics，Inc.，从2006年起担任总裁兼首席执行官，直到2016年该公司被Bio-Techne Corporation收购。在其职业生涯的早期，罗博士在生命科学公司Panomics，Inc.创立并担任过各种职务，在肿瘤学公司Exelixis, Inc.担任高级科学家。罗博士获中国科学技术大学化学学士学位，凯斯西储大学生物化学博士。
- Yuling Luo,is Alamar Biosciences, Inc. co-founder and has served as Alamar Biosciences, Inc. Chief Executive Officer and as Chairman of Alamar Biosciences, Inc. board of directors since May 2018. Dr. Luo also co-founded Attovia Therapeutics, Inc., where he has served a director since December 2022. Dr. Luo also co-founded Avida Biomed Inc., where he served as a director from January 2019 until it was acquired by Agilent Technologies, Inc. in December 2022. From August 2016 to February 2018, Dr. Luo served as President, Advanced Cell Diagnostics of Bio-Techne Corporation a biotechnology research company. Dr. Luo also co-founded Advanced Cell Diagnostics, Inc. where he served as President and Chief Executive Officer from 2006 until it was acquired by Bio-Techne Corporation in 2016. Earlier in his career, Dr. Luo founded and served in various roles at Panomics, Inc., a life sciences company, and as a Senior Scientist at Exelixis, Inc., an oncology company. Dr. Luo received his B.S. in Chemistry from the University of Science and Technology of China and holds a Ph.D. in Biochemistry from Case Western Reserve University.
- Timothy White
Timothy White，自2025年10月起担任Alamar Biosciences，Inc.总裁。在此之前，他于2021年3月至2025年10月担任Alamar Biosciences，Inc. 首席财务官和首席商务官。从2002年到2021年，White先生是EMA Partners，LLC（“EMA”）的创始人和管理成员，该公司是一家主要从事生命科学、诊断和医疗保健行业的精品投资银行。在创立EMA之前，White先生曾担任Packard BioScience公司的总法律顾问、副总裁和秘书。在此之前，White先生是丹佛Jacobs，Chase，Frick，Kleinkopf & Kelley，LLC律师事务所的交易律师，他的执业领域包括合并、收购、融资和证券工作。White先生的法律生涯始于Ballard，Spahr，Andrews & Ingersoll丹佛办事处的交易律师。怀特先生在汉密尔顿学院获得政府学士学位，并在密歇根大学法学院获得法学博士学位。
Timothy White,has served as Alamar Biosciences, Inc. President since October 2025. Prior to that, he served as Alamar Biosciences, Inc. Chief Financial Officer and Chief Business Officer from March 2021 to October 2025. From 2002 to 2021, Mr. White was the founder and Managing Member of EMA Partners, LLC ("EMA"), a boutique investment bank primarily in the life science, diagnostic and healthcare industries. Prior to founding EMA, Mr. White served as General Counsel, Vice President and Secretary of Packard BioScience Company. Prior to that, Mr. White was a transactional attorney at the Denver law firm of Jacobs, Chase, Frick, Kleinkopf & Kelley, LLC, where his practice included mergers, acquisitions, financings and securities work. Mr. White started his legal career as a transactional attorney in the Denver office of Ballard, Spahr, Andrews & Ingersoll. Mr. White received his B.S. in Government from Hamilton College and a J.D. from the University of Michigan Law School.- Timothy White，自2025年10月起担任Alamar Biosciences，Inc.总裁。在此之前，他于2021年3月至2025年10月担任Alamar Biosciences，Inc. 首席财务官和首席商务官。从2002年到2021年，White先生是EMA Partners，LLC（“EMA”）的创始人和管理成员，该公司是一家主要从事生命科学、诊断和医疗保健行业的精品投资银行。在创立EMA之前，White先生曾担任Packard BioScience公司的总法律顾问、副总裁和秘书。在此之前，White先生是丹佛Jacobs，Chase，Frick，Kleinkopf & Kelley，LLC律师事务所的交易律师，他的执业领域包括合并、收购、融资和证券工作。White先生的法律生涯始于Ballard，Spahr，Andrews & Ingersoll丹佛办事处的交易律师。怀特先生在汉密尔顿学院获得政府学士学位，并在密歇根大学法学院获得法学博士学位。
- Timothy White,has served as Alamar Biosciences, Inc. President since October 2025. Prior to that, he served as Alamar Biosciences, Inc. Chief Financial Officer and Chief Business Officer from March 2021 to October 2025. From 2002 to 2021, Mr. White was the founder and Managing Member of EMA Partners, LLC ("EMA"), a boutique investment bank primarily in the life science, diagnostic and healthcare industries. Prior to founding EMA, Mr. White served as General Counsel, Vice President and Secretary of Packard BioScience Company. Prior to that, Mr. White was a transactional attorney at the Denver law firm of Jacobs, Chase, Frick, Kleinkopf & Kelley, LLC, where his practice included mergers, acquisitions, financings and securities work. Mr. White started his legal career as a transactional attorney in the Denver office of Ballard, Spahr, Andrews & Ingersoll. Mr. White received his B.S. in Government from Hamilton College and a J.D. from the University of Michigan Law School.
- Justin McAnear
Justin McAnear，自2025年10月起担任Alamar Biosciences，Inc. 首席财务官。从2024年9月到2025年10月，McAnear先生在细胞疗法制造公司Cellares Corporation担任首席财务官。2018年10月至2024年8月，McAnear先生在生命科学技术公司10x Genomics, Inc.担任首席财务官。2015年8月至2018年10月，McAnear先生在汽车和清洁能源公司特斯拉公司担任全球财务和运营副总裁。在其职业生涯的早期，麦克阿尼尔曾在苹果公司、强生等公司担任过多个财务职务，并曾在美国海军担任过超过九年的海军飞行员。McAnear先生在美国海军学院获得系统工程学士学位，并拥有圣地亚哥大学金融硕士学位。
Justin McAnear,has served as Alamar Biosciences, Inc. Chief Financial Officer since October 2025. From September 2024 to October 2025, Mr. McAnear served as Chief Financial Officer of Cellares Corporation, a cell therapy manufacturing company. From October 2018 to August 2024, Mr. McAnear served as Chief Financial Officer of 10x Genomics, Inc., a life sciences technology company. From August 2015 to October 2018, Mr. McAnear was the Vice President of Worldwide Finance and Operations at Tesla, Inc., an automotive and clean energy company. Earlier in his career, Mr. McAnear served in various finance roles at Apple Inc., Johnson & Johnson and served over nine years as a naval aviator in the U.S. Navy. Mr. McAnear received his B.S. in Systems Engineering at the U.S. Naval Academy and holds an M.B.A. in Finance from the University of San Diego.- Justin McAnear，自2025年10月起担任Alamar Biosciences，Inc. 首席财务官。从2024年9月到2025年10月，McAnear先生在细胞疗法制造公司Cellares Corporation担任首席财务官。2018年10月至2024年8月，McAnear先生在生命科学技术公司10x Genomics, Inc.担任首席财务官。2015年8月至2018年10月，McAnear先生在汽车和清洁能源公司特斯拉公司担任全球财务和运营副总裁。在其职业生涯的早期，麦克阿尼尔曾在苹果公司、强生等公司担任过多个财务职务，并曾在美国海军担任过超过九年的海军飞行员。McAnear先生在美国海军学院获得系统工程学士学位，并拥有圣地亚哥大学金融硕士学位。
- Justin McAnear,has served as Alamar Biosciences, Inc. Chief Financial Officer since October 2025. From September 2024 to October 2025, Mr. McAnear served as Chief Financial Officer of Cellares Corporation, a cell therapy manufacturing company. From October 2018 to August 2024, Mr. McAnear served as Chief Financial Officer of 10x Genomics, Inc., a life sciences technology company. From August 2015 to October 2018, Mr. McAnear was the Vice President of Worldwide Finance and Operations at Tesla, Inc., an automotive and clean energy company. Earlier in his career, Mr. McAnear served in various finance roles at Apple Inc., Johnson & Johnson and served over nine years as a naval aviator in the U.S. Navy. Mr. McAnear received his B.S. in Systems Engineering at the U.S. Naval Academy and holds an M.B.A. in Finance from the University of San Diego.
- Shiping Chen
陈世平，是Alamar Biosciences，Inc.的联合创始人，自2018年8月起担任Alamar Biosciences，Inc.首席运营官，自2020年5月起担任Alamar Biosciences，Inc.董事会成员。2016年8月至2018年8月，陈博士在生物技术研究公司Bio-Techne Corporation担任先进细胞诊断部门的首席运营官。陈博士还与人共同创立了Advanced Cell Diagnostics，Inc.，这是一家诊断公司，他在2008年至2016年期间担任首席运营官。在其职业生涯早期，他曾在物流自动化公司Power Automation Systems担任工程总监，并与他人共同创立并担任生命科学公司Panomics，Inc.的首席技术官。此外，陈博士此前还曾担任马里兰大学机械工程学助理教授和伦敦南岸大学电气工程学高级讲师。陈博士获得中国科学技术大学精密仪器仪表工程学士学位，并获得伦敦大学电气与电子工程博士学位。
Shiping Chen,is Alamar Biosciences, Inc. co-founder and has served as Alamar Biosciences, Inc. Chief Operating Officer since August 2018 and as a member of Alamar Biosciences, Inc. board of directors since May 2020. From August 2016 to August 2018, Dr. Chen served as Chief Operating Officer of the Advanced Cell Diagnostics division at Bio-Techne Corporation, a biotechnology research company. Dr. Chen also co-founded Advanced Cell Diagnostics, Inc., a diagnostics company, where he served as Chief Operating Officer from 2008 to 2016. Earlier in his career, he served as Director of Engineering at Power Automation Systems, a logistics automation company, and co-founded and served as Chief Technology Officer of Panomics, Inc., a life sciences company. Additionally, Dr. Chen previously served as Assistant Professor of Mechanical Engineering at the University of Maryland and as a Senior Lecturer of Electrical Engineering at London South Bank University from. Dr. Chen received his B.S. in Precision Instrumentation Engineering from the University of Science and Technology of China and obtained a Ph.D. in Electrical and Electronic Engineering from the University of London.- 陈世平，是Alamar Biosciences，Inc.的联合创始人，自2018年8月起担任Alamar Biosciences，Inc.首席运营官，自2020年5月起担任Alamar Biosciences，Inc.董事会成员。2016年8月至2018年8月，陈博士在生物技术研究公司Bio-Techne Corporation担任先进细胞诊断部门的首席运营官。陈博士还与人共同创立了Advanced Cell Diagnostics，Inc.，这是一家诊断公司，他在2008年至2016年期间担任首席运营官。在其职业生涯早期，他曾在物流自动化公司Power Automation Systems担任工程总监，并与他人共同创立并担任生命科学公司Panomics，Inc.的首席技术官。此外，陈博士此前还曾担任马里兰大学机械工程学助理教授和伦敦南岸大学电气工程学高级讲师。陈博士获得中国科学技术大学精密仪器仪表工程学士学位，并获得伦敦大学电气与电子工程博士学位。
- Shiping Chen,is Alamar Biosciences, Inc. co-founder and has served as Alamar Biosciences, Inc. Chief Operating Officer since August 2018 and as a member of Alamar Biosciences, Inc. board of directors since May 2020. From August 2016 to August 2018, Dr. Chen served as Chief Operating Officer of the Advanced Cell Diagnostics division at Bio-Techne Corporation, a biotechnology research company. Dr. Chen also co-founded Advanced Cell Diagnostics, Inc., a diagnostics company, where he served as Chief Operating Officer from 2008 to 2016. Earlier in his career, he served as Director of Engineering at Power Automation Systems, a logistics automation company, and co-founded and served as Chief Technology Officer of Panomics, Inc., a life sciences company. Additionally, Dr. Chen previously served as Assistant Professor of Mechanical Engineering at the University of Maryland and as a Senior Lecturer of Electrical Engineering at London South Bank University from. Dr. Chen received his B.S. in Precision Instrumentation Engineering from the University of Science and Technology of China and obtained a Ph.D. in Electrical and Electronic Engineering from the University of London.